Dyve Biosciences announced today that Tatyana Beldock joined the company’s board of directors. Camarillo, California-based Dyve develops the DMAX delivery platform. Its transdermal drug delivery technology directly targets the acidic microenvironments that drive cancer cell growth and inflammation. “We are thrilled to have Tatyana join our board,” said Dr. Ryan Beal, CEO of Dyve. “Tatyana brings […]
dyvebioscience
Dyve Biosciences to collaborate with Moffitt Cancer Center on transdermal buffering agent
Dyve Biosciences announced today that it entered into a joint two-year research collaboration with the Moffit Cancer Center. Under the collaboration, Dyve and Moffit will study the former’s systemic buffering agent, DYV800, delivered through the company’s broadly applicable transdermal delivery technology, in various cancer laboratory models. According to a news release, the models through which […]
8 drug delivery innovations you need to know
The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the […]
Dyve Biosciences appoints Camilla V. Simpson to its board
Clinical-stage biotechnology company Dyve Biosciences announced this week that Camilla V. Simpson joined its board of directors. Simpson possesses over 25 years of experience in the biotech industry, currently serving as an independent member of the board of directors at Spruce Biosciences and as a member of the scientific advisory board at Aristea Therapeutics, according […]
Dyve Biosciences hires new chief scientific officer
Transdermal drug therapy developer Dyve Biosciences announced that it appointed longtime Pfizer executive Chuck Harbert to the role of chief scientific officer. Harbert spent three decades at Pfizer, serving as the company’s VP of U.S. exploratory development and strategic planning, among other senior positions with Pfizer Central Research. He is the inventor and co-inventor of 35 pharmaceutical […]
Dyve Bioscience touts proof-of-concept study for transdermal painkiller
Dyve Bioscience this week touted data from a human proof-of-concept pilot study of its transdermal sodium bicarbonate therapy for pain reduction in people with acute gout flare. The study enrolled 24 people with a history of gout. Those in the active treatment group were given lotion containing sodium bicarbonate and menthol, while those in the […]
